ubrogepant
Selected indexed studies
- Ubrogepant for the treatment of migraine. (Expert Opin Pharmacother, 2020) [PMID:32011192]
- Ubrogepant. (, 2012) [PMID:34324284]
- Ubrogepant. (, 2006) [PMID:33104317]
_Worker-drafted node — pending editorial review._
Connections
ubrogepant is a side effect of
Sources
- Ubrogepant for the treatment of migraine. (2020) pubmed
- Ubrogepant. (2012) pubmed
- Ubrogepant. (2006) pubmed
- Ubrogepant: First Approval. (2020) pubmed
- Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. (2023) pubmed
- Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. (2025) pubmed
- Ubrogepant and rimegepant: systematic review, meta-analysis, and meta-regression of clinical studies. (2023) pubmed
- Ubrogepant to Treat Acute Migraine in Adults. (2021) pubmed
- Ubrogepant for the Treatment of Migraine. (2019) pubmed
- Ubrogepant: An Oral Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist for Abortive Migraine Treatment. (2022) pubmed